An Open-label, Cross-over, Pharmacokinetic Study to Assess the Safety and Pharmacokinetics of Transdermal Granisetron (Sancuso Patch) and IV Granisetron in a Pediatric Oncology Population (Aged 6 to 12 Years)

Trial Profile

An Open-label, Cross-over, Pharmacokinetic Study to Assess the Safety and Pharmacokinetics of Transdermal Granisetron (Sancuso Patch) and IV Granisetron in a Pediatric Oncology Population (Aged 6 to 12 Years)

Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 10 Jun 2017

At a glance

  • Drugs Granisetron (Primary) ; Granisetron (Primary)
  • Indications Chemotherapy-induced nausea and vomiting
  • Focus Pharmacokinetics
  • Sponsors Kyowa Kirin International; Kyowa Kirin Pharmaceutical Development
  • Most Recent Events

    • 01 Mar 2017 Planned primary completion date changed from 1 May 2015 to 1 Dec 2017.
    • 01 Mar 2017 Planned initiation date changed from 1 Mar 2014 to 1 Mar 2017.
    • 23 Jan 2014 Planned initiation date changed from 1 Mar 2013 to 1 Mar 2014 according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top